



Original Effective Date: 12/06/2024  
Current Effective Date: 12/06/2024  
Last P&T Approval/Version: 10/30/2024  
Next Review Due By: 04/2025  
Policy Number: C28657-A

## Kisunla (donanemab-azbt)

### PRODUCTS AFFECTED

Kisunla (donanemab-azbt)

### COVERAGE POLICY

*Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.*

#### **Documentation Requirements:**

*Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.*

#### **DIAGNOSIS:**

Alzheimer's disease

#### **REQUIRED MEDICAL INFORMATION:**

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

#### **A. ALZHEIMER'S DISEASE:**

1. Documentation of a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease based on NIA-AA diagnostic criteria [A concern regarding cognition reported by the patient or informant or observed by the clinician, Objective evidence of impairment in one or more cognitive domains that is not explained by age or education, Preservation of independence in functional

## Drug and Biologic Coverage Criteria

abilities, Not demented] OR diagnosis of Alzheimer disease dementia based on NIA-AA criteria for probable AD dementia [See Appendix]

AND

2. Documentation of Clinical Dementia Rating Scale (CDR) Global Score of 0.5 or 1 OR Mini-Mental State Examination (MMSE) score between 20 and 28 OR Montreal Cognitive Assessment (MoCA) score of at least 16
- AND
3. Documentation of confirmation of underlying amyloid beta pathology [through PET scan OR lumbar puncture (LP) for CSF (cerebrospinal fluid)]
- AND
4. Documentation within medical record member does NOT have any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the member's cognitive impairment

### CONTINUATION OF THERAPY:

#### A. ALZHEIMER'S DISEASE:

1. Adherence to therapy at least 85% of the time as verified by the prescriber or member medication fill history OR adherence less than 85% of the time due to the need for surgery or treatment of an infection, causing temporary discontinuation
- AND
2. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity such as amyloid-related imaging abnormalities (ARIA)
- AND
3. Documentation of positive clinical response, as demonstrated by improvement OR stabilization in baseline cognitive scoring using the same testing method as provided during initial authorization request
- AND
4. Prescriber attests to monitoring amyloid plaque levels as clinically indicated
- Note: Consider stopping dosing with Kisunla based on reduction of amyloid plaques to minimal levels*
- AND
5. Documentation of new MRI prior to the 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, and 7<sup>th</sup> infusions, if applicable, showing radiographic stability.
- Note: If 10 or more new incident microhemorrhages or > 2 focal areas of superficial siderosis (radiographic severe ARIA-H) is observed, treatment may be continued with caution only after a clinical evaluation and a follow-up MRI demonstrates radiographic stabilization (i.e., no increase in size or number of ARIA-H).*

### DURATION OF APPROVAL:

Initial authorization: 3 months, Continuation of Therapy: 6 months

### PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with a Neurologist, Geriatrician, Geropsychiatric specialist, or Alzheimer's Disease Specialist [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

### AGE RESTRICTIONS:

60 years of age and older

### QUANTITY:

700 mg every four weeks for three doses (infusions 1, 2, and 3), then 1400 mg every four weeks (infusion 4 and beyond)

### PLACE OF ADMINISTRATION:

Molina Healthcare, Inc. confidential and proprietary © 2024

*This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.*

## Drug and Biologic Coverage Criteria

The recommendation is that infused medications in this policy will be for pharmacy or medical benefit coverage administered in a place of service that is a non-inpatient hospital facility-based location.

### DRUG INFORMATION

#### ROUTE OF ADMINISTRATION:

Intravenous

#### DRUG CLASS:

Alzheimer's Treatment - Anti-Amyloid Antibodies

#### FDA-APPROVED USES:

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.

#### COMPENDIAL APPROVED OFF-LABELED USES:

None

### APPENDIX

#### APPENDIX:

##### Criteria for all-cause dementia: Core clinical criteria

The diagnosis of dementia is intended to encompass the spectrum of severity, ranging from the mildest to the most severe stages of dementia. The methodology for staging of dementia severity was beyond the charge of the workgroup. Dementia is diagnosed when there are cognitive or behavioral (neuropsychiatric) symptoms that:

1. Interfere with the ability to function at work or at usual activities; and
2. Represent a decline from previous levels of functioning and performing; and
3. Are not explained by delirium or major psychiatric disorder.
4. Cognitive impairment is detected and diagnosed through a combination of (1) history-taking from the patient and a knowledgeable informant and (2) an objective cognitive assessment, either a "bedside" mental status examination or neuropsychological testing. Neuropsychological testing should be performed when the routine history and bedside mental status examination cannot provide a confident diagnosis.
5. The cognitive or behavioral impairment involves a minimum of two of the following domains:
  - a. Impaired ability to acquire and remember new information—symptoms include repetitive questions or conversations, misplacing personal belongings, forgetting events or appointments, getting lost on a familiar route.
  - b. Impaired reasoning and handling of complex tasks, poor judgment— symptoms include poor understanding of safety risks, inability to manage finances, poor decision-making ability, inability to plan complex or sequential activities.
  - c. Impaired visuospatial abilities—symptoms include inability to recognize faces or common objects or to find objects in direct view despite good acuity, inability to operate simple implements, or orient clothing to the body.
  - d. Impaired language functions (speaking, reading, writing)—symptoms include difficulty thinking of common words while speaking, hesitations; speech, spelling, and writing errors.
  - e. Changes in personality, behavior, or comportsment—symptoms include uncharacteristic mood fluctuations such as agitation, impaired motivation, initiative, apathy, loss of drive, social withdrawal, decreased interest in previous activities, loss of empathy, compulsive or obsessive behaviors, socially unacceptable behaviors.

### **Probable AD dementia is diagnosed when the patient:**

1. Meets criteria for dementia described above, and in addition, has the following characteristics:
  - A. Insidious onset. Symptoms have a gradual onset over months to years, not sudden over hours or days.
  - B. Clear-cut history of worsening of cognition by report or observation; and
  - C. The initial and most prominent cognitive deficits are evident on history and examination in one of the following categories.
    - a. Amnesic presentation: It is the most common syndromic presentation of AD dementia. The deficits should include impairment in learning and recall of recently learned information. There should also be evidence of cognitive dysfunction in at least one other cognitive domain, as defined earlier in the text.
    - b. Non-amnesic presentations:
      - Language presentation: The most prominent deficits are in word-finding, but deficits in other cognitive domains should be present.
      - Visuospatial presentation: The most prominent deficits are in spatial cognition, including object agnosia, impaired face recognition, simultanagnosia, and alexia. Deficits in other cognitive domains should be present.
      - Executive dysfunction: The most prominent deficits are impaired reasoning, judgment, and problem solving. Deficits in other cognitive domains should be present.
  - D. The diagnosis of probable AD dementia **should not** be applied when there is evidence of (a) substantial concomitant cerebrovascular disease, defined by a history of a stroke temporally related to the onset or worsening of cognitive impairment; or the presence of multiple or extensive infarcts or severe white matter hyperintensity burden; or (b) core features of Dementia with Lewy bodies other than dementia itself; or (c) prominent features of behavioral variant frontotemporal dementia; or (d) prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive aphasia; or (e) evidence for another concurrent, active neurological disease, or a non- neurological medical comorbidity or use of medication that could have a substantial effect on cognition.

### **Common Cognitive Assessments**

**Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog 13)** A 13-item test used to measure the amount or degree of cognitive impairment based on the domains of attention, concentration, memory, language, and praxis. It is currently the preferred test for measuring the effectiveness of anti-dementia treatments, with current studies taking place in the MCI population. Because the ADAS-Cog is given verbally with a heavy emphasis on spoken language, the patient must be fluent in the language in which the test is given. The ADAS-Cog is translated into 81 languages.

**Clinical Dementia Rating Scale–Sum of Boxes (CDR–SB)** Uses a 5-point scale that identifies 6 cognitive and functional performance domains affected by AD and other dementias. Information is acquired through patient interviews and reliable reporting from a caregiver or member of the patient’s family. This test has been shown to be effective in correctly staging AD and MCI. This test is available in more than 40 languages.

**Mini-Cognitive Assessment Instrument (Mini-Cog)** A 3-minute assessment used as part of a complete diagnostic workup designed to help detect cognitive impairment in older adults. In the Mini-Cog, the patient is asked to recall 3 items and then draw a clock. The test is accurate and accessible to many populations, including non-English speakers.

**Mini-Mental State Examination (MMSE)** A test that measures cognition and has been used to stage and show changes over time. This assessment is available in more than 70 languages and dialects

## Drug and Biologic Coverage Criteria

**Self-Administered Gerocognitive Examination (SAGE)** measures cognitive function in the domains of orientation, language, memory, executive function, calculations, abstraction and visuospatial abilities. Takes roughly 10-15 minutes to complete.

**St Louis University Mental Status (SLUMS)** Measures cognitive function in the domains of orientation, attention (digit span), numeric calculation, immediate and delayed verbal recall, verbal fluency (animal naming), executive functions, figure recognition/size differentiation and immediate recall of contextual verbal information- takes 7 minutes to complete.

**Montreal Cognitive Assessment (MoCA)** Brief screening measure consisting of a 30-point test administered in 10 minutes, focusing on memory, visuospatial, executive and language function and orientation to time and place.

## BACKGROUND AND OTHER CONSIDERATIONS

### BACKGROUND:

Kisunla is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. It reduces amyloid beta plaques in the brain, which is a defining pathophysiological feature of Alzheimer disease.

The safety and efficacy of Kisunla was evaluated in a Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group 18-month study, Study 1 (NCT04437511) in adult patients with early AD (confirmed presence of amyloid pathology and MCI or mild dementia stage of disease, consistent with Stage 3 and Stage 4 AD) with amyloid and low/medium or high tau levels based on PET imaging. Patients were randomized 1:1 to receive one of the following for up to 72 weeks: Kisunla 700 mg IV Q4W for the first 3 doses, and then 1400 mg Q4W (n = 860), or Placebo IV (n = 876). The treatment was switched to placebo based on amyloid PET levels measured at Week 24, Week 52, and Week 76. If the amyloid plaque level was <11 Centiloids on a single PET scan or 11 to <25 Centiloids on 2 consecutive PET scans, the patient was eligible to be switched to placebo. Change in integrated Alzheimer's Disease Rating Scale (iADRS) score from baseline to Week 76 served as the primary endpoint. Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76 in the combined population (2.92, P <0.0001) and the low/medium tau population (3.25, P <0.0001). Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) compared to placebo at Week 76 in the combined population (-0.70, P <0.0001). There were also statistically significant differences (P <0.001) between treatment groups as measured on the Alzheimer's Disease Assessment Scale – 13-item Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer's Disease Cooperative Study – Instrumental Activities of Daily Living (ADCS-iADL) scale at Week 76.

In Study 1, the most common adverse reactions reported in at least 10% of patients treated with Kisunla and having higher incidence compared to patients on placebo were ARIA-E, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and headache. Adverse events, including infusion-related reactions, occurred in 8.7% of patients. ARIA-E occurred in 24.0% (52 symptomatic patients) in Kisunla arm vs. 2.1% (0 symptomatic patients during study) in placebo arm.

### Risk Factors for ARIA and Intracerebral Hemorrhage

Patients were excluded from enrollment in Study 1 based on findings on neuroimaging of prior intracerebral hemorrhage >1 cm in diameter, >4 microhemorrhages, >1 area of superficial siderosis, severe white matter disease, or vasogenic edema.

## Drug and Biologic Coverage Criteria

The label also includes the addition of a black box warning for amyloid related imaging abnormalities. Warning is inclusive of ApoE ε4 homozygotes who were found to have a higher incidence of ARIA compared to heterozygotes and noncarriers.

### CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Kisunla (donanemab-azbt) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to Kisunla (donanemab-azbt) include: patients with known serious hypersensitivity to donanemab-azbt or to any of the excipients.

### OTHER SPECIAL CONSIDERATIONS:

Kisunla (donanemab-azbt) has a Black Box Warning for amyloid related imaging abnormalities. Monoclonal antibodies directed against aggregated forms of beta amyloid, including Kisunla, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). ARIA is usually asymptomatic, although rarely serious and life-threatening events can occur. Serious intracerebral hemorrhage greater than 1 cm have occurred in patients treated with this class of medications. Patients treated with this class of medications, including Kisunla, who are ApoE ε4 homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Consider the benefit of Kisunla for the treatment of Alzheimer's disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with Kisunla.

## CODING/BILLING INFORMATION

**CODING DISCLAIMER.** Codes listed in this policy are for reference purposes only and may not be all-inclusive or applicable for every state or line of business. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry-standard coding practices for all submissions. Molina has the right to reject/deny the claim and recover claim payment(s) if it is determined it is not billed appropriately or not a covered benefit. Molina reserves the right to revise this policy as needed.

HCPCS CODE	DESCRIPTION
J0175	Injection, donanemab-azbt, 2 mg

### AVAILABLE DOSAGE FORMS:

Kisunla SOLN 350MG/20ML (17.5 mg/mL) single-dose vial

**REFERENCES**

1. Kisunla (donanemab) injection, for intravenous use [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2024.
2. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2) (2024) Clinicaltrials.gov. Available at: <https://clinicaltrials.gov/study/NCT04437511> (Accessed: 09 September 2024).
3. 2024 Alzheimer’s disease facts and figures. *Alzheimers Dement*. 2024;20(5):3708-3821. doi:10.1002/alz.13809
4. Mintun MA, et al. Donanemab in early Alzheimer's disease. *N Engl J Med*. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708
5. Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512–527. doi:10.1001/jama.2023.13239
6. Wessels AM, et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer's Disease Rating Scale (iADRS). *J Prev Alzheimers Dis*. 2015;2(4):227-241. doi:10.14283/jpad.2015.82
7. Wessels AM, et al. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates. *Alzheimers Dement (N Y)*. 2022;8(1):e12312. Published June 6, 2022. doi:10.1002/trc2.12312
8. Wessels AM, et al. Meaningful clinical changes in Alzheimer disease measured with the iADRS and illustrated using the donanemab TRAILBLAZER-ALZ study findings. *Neurol Clin Pract*. 2023;13(2):e200127. doi:10.1212/CPJ.0000000000200127

SUMMARY OF REVIEW/REVISIONS	DATE
NEW CRITERIA CREATION	Q4 2024